Article
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
Cancer discovery - 1 May 2014
Grabiner Brian C, Nardi Valentina, Birsoy Kıvanc, Possemato Richard, Shen Kuang, Sinha Sumi, Jordan Alexander, Beck Andrew H, Sabatini David M
Abstract excerpt
Genes encoding components of the PI3K-AKT-mTOR signaling axis are frequently mutated in cancer, but few mutations have been characterized in MTOR, the gene encoding the mTOR kinase. Using publicly available tumor genome sequencing data, we generated a comprehensive catalog of mTOR pathway mutations in cancer, identifying 33 MTOR mutations that confer pathway hyperactivation. The mutations cluster in six distinct...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.